Meletios Athanasios Dimopoulos
Overview
Explore the profile of Meletios Athanasios Dimopoulos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
1117
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mukhopadhyay P, Abdullah H, Opalinska J, Paka P, Richards E, Weisel K, et al.
Blood Cancer J
. 2025 Feb;
15(1):15.
PMID: 39920159
Patients with relapsed/refractory multiple myeloma (RRMM) have a poor prognosis and a need remains for novel effective therapies. Belantamab mafodotin, an anti-B-cell maturation antigen antibody-drug conjugate, was granted accelerated/conditional approval...
2.
Spiliopoulou P, Rousakis P, Panteli C, Eleutherakis-Papaiakovou E, Migkou M, Kanellias N, et al.
Scand J Med Sci Sports
. 2025 Jan;
35(2):e70020.
PMID: 39853819
The purpose of the study was to investigate the effects of exercise training on the bone marrow immune microenvironment and on minimal residual disease of multiple myeloma patients who completed...
3.
Aravantinou-Fatorou A, Georgakopoulou V, Dimopoulos M, Liontos M
Biomed Rep
. 2025 Jan;
22(3):43.
PMID: 39810899
The advent of personalized and precision medicine has revolutionized oncology and treatment of gynecological cancer. These innovative approaches tailor treatments to individual patient profiles beyond genetic markers considering environmental and...
4.
Kyriazoglou A, Papachristou D, Moutafi M, Papakosta A, Papatheodoridi A, Kaparelou M, et al.
Anticancer Res
. 2024 Jul;
44(8):3331-3336.
PMID: 39060085
Background/aim: Uterine leiomyosarcomas (uLMS) are the most common mesenchymal tumors of the female genital tract. uLMS genetics encompass complex karyotypes with no specific molecular alterations. The Hippo pathway has been...
5.
Dimopoulos M, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, et al.
N Engl J Med
. 2024 Jun;
391(5):408-421.
PMID: 38828951
Background: Triplet or quadruplet therapies incorporating proteasome inhibitors, immunomodulators, and anti-CD38 antibodies have led to prolonged survival among patients with newly diagnosed multiple myeloma; however, most patients have a relapse....
6.
Efentakis P, Varela A, Lamprou S, Papanagnou E, Chatzistefanou M, Christodoulou A, et al.
Br J Pharmacol
. 2024 Apr;
181(16):2964-2990.
PMID: 38679957
Background And Purpose: Cancer therapy-related cardiovascular adverse events (CAEs) in presence of comorbidities, are in the spotlight of the cardio-oncology guidelines. Carfilzomib (Cfz), indicated for relapsed/refractory multiple myeloma (MM), presents...
7.
Apostolidou K, Zografos E, Papatheodoridi M, Fiste O, Dimopoulos M, Zagouri F
Breast
. 2024 Apr;
75:103729.
PMID: 38599049
Over the past few decades, first-line therapy for treating advanced and metastatic HR+/HER2-breast cancer has transformed due to the introduction of adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitors (CDK...
8.
Efentakis P, Choustoulaki A, Kwiatkowski G, Varela A, Kostopoulos I, Tsekenis G, et al.
Basic Res Cardiol
. 2024 Mar;
120(1):263-286.
PMID: 38520533
Immune checkpoint inhibitors (ICIs) exhibit remarkable antitumor activity and immune-related cardiotoxicity of unknown pathomechanism. The aim of the study was to investigate the ICI class-dependent cardiotoxicity in vitro and pembrolizumab's...
9.
Perrot A, Delimpasi S, Spanoudakis E, Frolund U, Belotti A, Oriol A, et al.
Leuk Lymphoma
. 2024 Mar;
65(6):833-842.
PMID: 38497533
Once-weekly carfilzomib at 56 mg/m plus immunomodulatory drugs and dexamethasone has shown efficacy and tolerability treating early relapsed/refractory multiple myeloma (RRMM). The phase 2 SELECT study (NCT04191616) evaluated efficacy/safety of...
10.
Rodolakis I, Liontos M, Pergialiotis V, Haidopoulos D, Kaparelou M, Vlachos D, et al.
Eur J Obstet Gynecol Reprod Biol
. 2024 Mar;
296:233-238.
PMID: 38479209
Objective: The chemotherapy response score (CRS) has been widely adopted as a predictive tool for ovarian cancer survival. In the present study, we seek to define differences in survival rates...